Study of Platinum Plus Etoposide With or Without BGB-A317 in Participants With Untreated Extensive-Stage Small Cell Lung Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
This is a randomized, double‐blind, placebo‐controlled, multicenter, Phase 3 study to compare the efficacy of tislelizumab + cisplatin or carboplatin + etoposide (Arm A) and placebo + cisplatin or carboplatin + etoposide (Arm B) as first‐line treatment in approximately 455 participants who have previously untreated extensive‐stage small cell lung cancer (ES‐SCLC)
Epistemonikos ID: 50a8ca45215d2da295c8da8f1bcdd263e6b359dd
First added on: May 22, 2024